Abstracts tagged "gout"

Abstract Number: 2353 • 2015 ACR/ARHP Annual Meeting
Lesinurad and Febuxostat Combination Therapy: Analysis of Treatment Based on Patient Baseline Renal Function
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Scott Adler⁶, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁵, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: A randomized, double-blind, placebo-controlled, Phase III clinical trial showed that lesinurad, a selective uric acid reabsorption inhibitor (SURI), in combination with febuxostat 80 mg…
Abstract Number: 227 • 2015 ACR/ARHP Annual Meeting
Impact of Gout on the Risk of Atrial Fibrillation
Chang-Fu Kuo¹, Matthew J. Grainge², Weiya Zhang³ and Michael Doherty⁴, ¹Division of Rheumatoplogy, Allergy and Immunology, Chang Gung Memorial Hospital, Tayuan, Taiwan, ²Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom, ³Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ⁴Academic Rheumatology, City Hospital, Nottingham, United Kingdom
Background/Purpose: To examine the risk of atrial fibrillation (AF) at the time of first diagnosis of gout compared to matched controls and to follow incident…
Abstract Number: 2112 • 2015 ACR/ARHP Annual Meeting
Analysis of Gout Subjects Receiving Lesinurad and Allopurinol Combination Therapy By Baseline Renal Function
Kenneth G. Saag¹, Thomas Bardin², Alexander So^3,4, Puja Khanna⁵, Chris Storgard⁶, Scott Baumgartner⁷, Maple Fung⁷, Nihar Bhakta⁷, Scott Adler⁸, Jeff Kopicko⁷ and Michael A. Becker⁹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Lariboisière Hospital, Paris, France, ³Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ⁴CHU Vaudois, University of Lausanne, Lausanne, Switzerland, ⁵Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Ardea Biosciences, Inc., San Diego, CA, ⁸AstraZeneca Pharmaceuticals, Wilmington, DE, ⁹University of Chicago, Chicago, IL
Background/Purpose: Two randomized, double-blind, placebo-controlled Phase III clinical trials showed that lesinurad (200 or 400 mg) when added to allopurinol (200-900 mg) significantly increased the…
Abstract Number: 2354 • 2015 ACR/ARHP Annual Meeting
The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors
Robert Terkeltaub¹, Fernando Perez-Ruiz^2,3,4, Jeff Kopicko⁵, Maple Fung⁵, Scott Adler⁶, Chris Storgard⁷, Scott Baumgartner⁵ and Nicola Dalbeth⁸, ¹Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ²Rheumatology Division, Hospital Universitario Cruces, Barakaldo, Spain, ³BioCruces Health Research Institute, Baracaldo, Spain, ⁴Servicio de Reumatologia, Hospital De Cruces, Baracaldo, Spain, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Previous studies have shown that long-term urate-lowering therapy (ULT) is required for improvements in gout flare frequency and tophi reduction, and that lower serum…
Abstract Number: 231 • 2015 ACR/ARHP Annual Meeting
Uric Acid Levels Predict Mortality in Women
Jenni E Kauppi¹, Tuomo Nieminen^2,3, Mika Kähönen^4,5, Anne Kerola⁶, Antti Jula⁷, Jaana Leiviskä⁸ and Markku J. Kauppi^9,10, ¹School of medicine, University of Tampere, Tampere, Finland, ²Department of Internal Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ³Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, ⁴Department of Clinical physiology, School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Clinical Physiology, Medical Imaging Centre, Pirkanmaa Hospital District, Tampere, Finland, ⁶Faculty of Medicine, University of Helsinki, Helsinki, Finland, ⁷Department of Health, National Institute for Health and Welfare, Turku, Finland, ⁸Department of Health, National Institute for Health and Welfare, Helsinki, Finland, ⁹School of Medicine, University of Tampere, Tampere, Finland, ¹⁰Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland
Background/Purpose: Hyperuricemia induces chronic inflammation and is associated with many diseases such as metabolic syndrome, high blood pressure, chronic kidney disease and cardiovascular diseases. The…
Abstract Number: 2113 • 2015 ACR/ARHP Annual Meeting
Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁶, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: Lesinurad (LESU; RDEA594) is a selective uric acid reabsorption inhibitor (SURI) being investigated for the treatment of gout in combination with a xanthine oxidase…
Abstract Number: 3165 • 2015 ACR/ARHP Annual Meeting
Do Omega-3 Fatty Acids Reduce Risk of Recurrent Gout Attacks?
MaryAnn Zhang¹, Yuqing Zhang², Robert Terkeltaub³, Clara Chen⁴ and Tuhina Neogi², ¹Internal Medicine, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴Boston University School of Public Health, Boston, MA
Background/Purpose: Current guidelines for gout management, based in part on epidemiologic data for development of incident gout, recommend limiting intake of high-purine fish. However,…
Abstract Number: 2963 • 2014 ACR/ARHP Annual Meeting
The URAT1 Uric Acid Transporter Is Important in Uric Acid Homeostasis and Its Activity May be Altered in Gout Patients and in Drug-Induced Hyperuricemia
Philip K. Tan, Sha Liu and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout results from chronic hyperuricemia. Most gout patients exhibit an increased renal reabsorption of uric acid which leads to elevated levels of serum uric…
Abstract Number: 166 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment
Myeong Jae Yoon¹, Ji Ae Yang², Sang Hyun Joo¹, Sang Jin Lee¹, Jin Young Moon¹, Hyun Mi Kwon¹, Dong Jin Ko¹, Yeong Wook Song¹ and Eun Bong Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose Gout is a recurrent inflammatory arthritis caused by crystal deposition of monosodium urate, which can be prevented urate-lowering agents such as allopurinol. However, gout…
Abstract Number: 2176 • 2014 ACR/ARHP Annual Meeting
Macrophages-Mediated Response to Uric Acid Crystals Is Modulated By Their Functional Polarization
Emma Garcia-Melchor¹, Monica Guma², Jordi Yagüe¹, Manel Juan¹ and Jacquie Harper³, ¹Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Arthritis and Inflammation Group, Malaghan Institute of Medical Research, Wellington, New Zealand
Background/Purpose: Macrophages have been involved in both initiation and resolution of gout flares. Accordingly, these cells are characterized by their plasticity as the environment modulates…
Abstract Number: 165 • 2014 ACR/ARHP Annual Meeting
Prevalence of Gout in the Adult Population of France in 2013
Thomas Bardin¹, Pierre Clerson², Stéphane Bouée³, Gerard H. Chales⁴, Michael Doherty⁵, René-Marc Flipo⁶, Charles Lambert⁷, Frédéric Lioté⁸, Thierry Poireaud⁹, Thierry Schaeverbeke¹⁰ and Pascal Richette¹¹, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²Orgametrie, Roubaix, France, ³Cemka, Bourg la Reine, France, ⁴Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ⁵Division of Rheumatology, Orthopedics and Dermatology, University of Nottingham, Nottingham, United Kingdom, ⁶rheumatology, Rene Salengro hospital, Lille, France, ⁷Ipsen, Boulogne Billancourt, France, ⁸Hôpital Lariboisière & University Paris Diderot, Paris, France, ⁹Menarini, Rungis, France, ¹⁰Rheumatology, Bordeaux University Hospital, Bordeaux, France, ¹¹INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France
Background/Purpose The prevalence of gout has been studied in several Western countries by various methods to approach gout diagnosis, and has been estimated to vary…
Abstract Number: 2179 • 2014 ACR/ARHP Annual Meeting
The Monocyte-Phagocyte System in Gout: Enhanced Inflammasome Activity and Expansion of CD14++CD16+ Monocytes in Patients with Gout
Emma Garcia-Melchor¹, Cesar Diaz-Torne², Monica Guma^3,4, Europa Azucena Gonzalez-Navarro⁵, Francesc Xavier Alemany⁶, Jordi Yagüe¹ and Manel Juan¹, ¹Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain, ²Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ⁴Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁵Immunology, Hospital Clinic Barcelona, Barcelona, Spain, ⁶Emergency, Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose: The central role of the monocyte-macrophage system in gout has been highlighted during the last years. Macrophages initiate the inflammatory response to monosodium urate…
Abstract Number: 160 • 2014 ACR/ARHP Annual Meeting
All Men with Gout Should be Screened for Erectile Dysfunction
Naomi Schlesinger¹, Diane C. Radvanski² and John Kostis³, ¹Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Department of Medicine, Division of Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ³Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose Erectile dysfunction (ED) is common in the general population. The likelihood of ED increases progressively with age; however, it is not an inevitable consequence…
Abstract Number: 1873 • 2014 ACR/ARHP Annual Meeting
Food Sources of Protein and Risk of Incident Gout in the Singapore Chinese Health Study
Gim Gee Teng^1,2, An Pan³, Jian-Min Yuan⁴ and Woon-Puay Koh^3,5, ¹Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore, ²Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ³Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, ⁴Division of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, and Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁵Duke-NUS Graduate Medical School Singapore, Singapore, Singapore

Background/Purpose: The Health Professional Follow up Study in Caucasian men showed that intakes of meat and seafood increased risk of gout, while dairy products, especially…
Abstract Number: 157 • 2014 ACR/ARHP Annual Meeting
Can We Diagnose Acute Gout without Joint Aspiration? Results of a Prospective Study of 112 Patients Presenting with Acute Arthritis
Pascal Zufferey, Roxana Valcov, Isabelle Fabreguet, Alexandre Dumusc and Alexander So, DAL, RHU/CHUV, Lausanne, Switzerland
Background/Purpose The gold standard for the diagnosis of acute MSU induced arthritis is crystal identification by microscopy after joint aspiration. Alternative diagnostic tools that have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].